| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 29.01. | Incannex erweitert klinischen Beirat für PSX-001-Programm um drei Experten | 1 | Investing.com Deutsch | ||
| INCANNEX HEALTHCARE Aktie jetzt für 0€ handeln | |||||
| 29.01. | Incannex appoints three experts to clinical advisory board for PSX-001 | 1 | Investing.com | ||
| 29.01. | Incannex Healthcare Announces Additional Appointments to Clinical Advisory Board | 1 | GlobeNewswire (USA) | ||
| 29.01. | Incannex Healthcare Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.01. | Incannex gründet klinischen Beirat für Therapie gegen Angststörungen | 2 | Investing.com Deutsch | ||
| 22.01. | Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program | 138 | GlobeNewswire (Europe) | MELBOURNE, Australia and NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies... ► Artikel lesen | |
| 22.01. | Incannex Healthcare Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.01. | Jahreshauptversammlung von Incannex Healthcare: Direktoren gewählt und Prüfer bestätigt | 1 | Investing.com Deutsch | ||
| 14.01. | Incannex Healthcare Delivers Transformational 2025 Progress and Outlines Well-Funded Outlook for 2026 | 245 | GlobeNewswire (Europe) | MELBOURNE, Australia and NEW YORK, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies... ► Artikel lesen | |
| 14.01. | Incannex Healthcare Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.12.25 | Incannex Healthcare Inc. - 8-K, Current Report | - | SEC Filings | ||
| 03.12.25 | Why Incannex Is Rising In Pre-market? | 1 | RTTNews | ||
| 03.12.25 | Incannex erhält Fast-Track-Status der FDA für Medikament gegen Schlafapnoe | 4 | Investing.com Deutsch | ||
| 03.12.25 | FDA grants fast track designation to Incannex's OSA treatment | 2 | Investing.com | ||
| 03.12.25 | Incannex Healthcare: Incannex Granted FDA Fast Track Designation for IHL-42X in Obstructive Sleep Apnea (OSA) | 277 | GlobeNewswire (Europe) | MELBOURNE, Australia and NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies... ► Artikel lesen | |
| 03.12.25 | Incannex Healthcare Inc. - 8-K, Current Report | - | SEC Filings | ||
| 14.11.25 | Incannex Healthcare Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 14.11.25 | Incannex Healthcare Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 30.10.25 | Incannex Healthcare Inc. - 8-K, Current Report | 14 | SEC Filings | ||
| 22.10.25 | Incannex granted extension by Nasdaq to regain compliance with minimum bid price requirement | 1 | Seeking Alpha |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 15,440 | +1,65 % | BERENBERG stuft ECKERT & ZIEGLER auf 'Buy' | HAMBURG (dpa-AFX Analyser) - Die Privatbank Berenberg hat die Einstufung für Eckert & Ziegler mit einem Kursziel von 24 Euro auf "Buy" belassen. Die vorläufigen Zahlen für 2025 hätten beim Umsatz und... ► Artikel lesen | |
| MCKESSON | 793,40 | -1,07 % | McKesson Corp. Reports Rise In Q3 Bottom Line | WASHINGTON (dpa-AFX) - McKesson Corp. (MCK) revealed earnings for its third quarter that Increases, from last yearThe company's earnings totaled $1.186 billion, or $9.59 per share. This compares... ► Artikel lesen | |
| SENSEONICS | 5,900 | -6,35 % | Senseonics Holdings, Inc.: Senseonics Receives European Approval for Eversense 365, World's Longest-lasting Continuous Glucose Monitor | GERMANTOWN, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 4,000 | +1,52 % | Perspective Therapeutics Prices Approx. $175 Mln Offering Of Shares And Pre-Funded Warrants | ||
| SRX HEALTH SOLUTIONS | 0,127 | -1,17 % | SRx Health Solutions, Inc.: SRx Health Solutions Launches EventHorizonIQ, a Public Ledger of AI-Generated Financial Market Instability Signals | ||
| ITONIC | 0,390 | +9,92 % | Pheton Holdings Ltd. Announces Corporate Name Change and Stock Ticker Symbol Change | BEIJING, China, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pheton Holdings Ltd (the "Company" or "Pheton"), a healthcare solution provider specializing in treatment planning systems for brachytherapy and other... ► Artikel lesen | |
| MOVANO | 13,960 | +3,79 % | Movano Inc. - S-4/A, Registration of securities, business combinations | ||
| SIEMENS HEALTHINEERS | 41,400 | -2,82 % | HV-Termine: Hauptversammlungen bei Adv. Blockchain, Aurubis, Fortec, Schott, Siemens, Healthineers, Stabilus, TUI | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 40,640 | +0,40 % | Fresenius Medical Care: Ein Neuanfang nach turbulenten Zeiten? | ||
| FRESENIUS | 49,760 | +1,06 % | JEFFERIES stuft Fresenius SE auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Fresenius mit einem Kursziel von 55 Euro auf "Buy" belassen. Die Bad Homburger seien in Verjüngungskur, und der Markt preise... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 28,740 | +4,89 % | PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance | SAN JOSE, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 39,680 | +3,44 % | BrightSpring Health Services, Inc. to Announce Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 | ||
| CARL ZEISS MEDITEC | 27,520 | +0,66 % | BARCLAYS stuft CARL ZEISS MEDITEC AG auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Carl Zeiss Meditec von 49 auf 32 Euro gesenkt und die Aktien von "Overweight" auf "Equal Weight" abgestuft. Nur... ► Artikel lesen | |
| HEARTFLOW | 27,690 | +6,54 % | Heartflow, Inc.: Heartflow FFRCT Analysis Delivers Prognostic Power and Significant Cost Savings in New Analyses of Over 90,000 Patients with Coronary Artery Disease | Lesion-specific FFRCT predicts individual cardiovascular outcomes and delivers greater-than-modeled cost savings for real-world population in FISH&CHIPS analyses from England's National Health ServiceMOUNTAIN... ► Artikel lesen | |
| GENEDX | 84,35 | +0,32 % | GeneDx to Participate in Upcoming Investor Conferences | GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced that company management will participate in upcoming investor conferences:
Stifel... ► Artikel lesen |